Pelthos Therapeutics Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Revenue | $15.6M | $10.9M | $9.4M | $7.4M | $0 | $0 |
| Cost of Revenue | $3.6M | $1.7M | $1.7M | $2.3M | $0 | $0 |
| Gross Profit | $12.0M | $9.2M | $7.7M | $5.1M | $0 | $0 |
| Gross Margin | 76.9% | 84.7% | 82.2% | 68.7% | — | — |
| Operating Expenses | ||||||
| Research & Development | $600.0K | $186.0K | $374.0K | $145.0K | $515.0K | $194.0K |
| SG&A Expense | $27.7M | $21.1M | $18.5M | $19.6M | $2.7M | $1.6M |
| Operating Income | $-17.3M | $-13.1M | $-12.0M | $-15.4M | $-3.2M | $-1.8M |
| Operating Margin | -111.0% | -120.0% | -127.8% | -207.4% | — | — |
| Interest Expense | — | — | — | $1.3M | — | $1.8K |
| Pretax Income | $-23.4M | $-25.1M | $-28.6M | $-16.7M | $-3.4M | $-2.0M |
| Income Tax Expense | $0 | $0 | $-6.9M | $-465.0K | $0 | $0 |
| Net Income | $-23.4M | $-25.1M | $-21.7M | $-16.2M | $-3.4M | $-2.0M |
| Net Margin | -150.1% | -229.9% | -230.7% | -219.3% | — | — |
| EPS (Basic) | $-6.62 | $-7.57 | $-9.24 | $-1.77 | $-1.76 | $-1.07 |
| EPS (Diluted) | $-6.62 | $-7.57 | $-9.24 | $-1.77 | $-1.76 | $-1.07 |
| Shares Outstanding (Basic) | 3.5M | 3.3M | 1.9M | 9.2M | 2.0M | 1.8M |
| Shares Outstanding (Diluted) | 3.5M | 3.3M | 1.9M | 9.2M | 2.0M | 1.8M |
| Dividends Per Share | — | — | — | — | — | — |